<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-103727</identifier>
<setSpec>1699-258X</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">New targets in systemic lupus (part 2/2)</dc:title>
<dc:description xml:lang="en">Glucocorticoids, aspirin, conventional antimalarials and immunosuppressants are the mainstay of treatment of Systemic Lupus Erythematosus (SLE). Until recently, the first three were the only agents approved for treatment. A better understanding of the pathophysiology of the immune system has identified new therapeutic targets. In fact, belimumab, a human monoclonal antibody to BLyS inhibitor has become, in recent months, the first drug approved for the treatment of SLE since 1957, underscoring difficulties of all kinds, including economic and organizational ones inherent to clinical trials on this disease. Many other molecules are in various stages of development and soon will have concrete results. In this review, we examined the mechanism of action and most relevant clinical data for these molecules(AU)</dc:description>
<dc:creator>Lois Iglesias, Ana</dc:creator>
<dc:creator>García Villanueva, María J</dc:creator>
<dc:creator>Zea Mendoza, Antonio C</dc:creator>
<dc:creator>Sifuentes Giraldo, Walter A</dc:creator>
<dc:creator>Boteanu, Alina L</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Glucocorticoides, aspirina, antipalúdicos e inmunosupresores convencionales constituyen la base del tratamiento del lupus eritematoso sistémico (LES). Hasta recientemente, los 3 primeros eran los únicos agentes aprobados para su tratamiento. El mejor conocimiento de la fisiopatología del sistema inmunitario ha permitido identificar nuevas dianas terapéuticas. De hecho, belimumab, un anticuerpo monoclonal humano inhibidor de BLyS, se ha convertido hace pocos meses en el primer fármaco aprobado para el tratamiento del LES desde 1957, lo que subraya las dificultades de todo tipo, incluyendo las económicas y organizativas, inherentes a los ensayos clínicos sobre esta enfermedad. Otras muchas moléculas se encuentran en distintas fases de desarrollo y en poco tiempo dispondremos de resultados concretos. En esta revisión repasamos el mecanismo de acción y los datos clínicos más relevantes de estas moléculas(AU)</dc:description>
<dc:source>Reumatol. clín. (Barc.);8(5): 263-269, sep.-oct.2012.</dc:source>
<dc:identifier>ibc-103727</dc:identifier>
<dc:title xml:lang="es">Nuevas dianas terapéuticas en el lupus sistémico (parte 2/2)</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d1716^s22074</dc:subject>
<dc:subject>^d8356^s22080</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d8356^s22067</dc:subject>
<dc:subject>^d24555</dc:subject>
<dc:subject>^d6082^s22073</dc:subject>
<dc:subject>^d8356^s22054</dc:subject>
<dc:subject>^d23473^s22026</dc:subject>
<dc:subject>^d1716^s22066</dc:subject>
<dc:subject>^d24555^s22021</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d1716^s22045</dc:subject>
<dc:subject>^d31646^s22021</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d31646^s22031</dc:subject>
<dc:subject>^d965^s22073</dc:subject>
<dc:subject>^d7344^s22073</dc:subject>
<dc:subject>^d1716^s22039</dc:subject>
<dc:type>article</dc:type>
<dc:date>201210</dc:date>
</metadata>
</record>
</ibecs-document>
